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marketing activity by brand name drugs. Estimates were small, significant, and 
positive (feed-forward neural networks indicated an even stronger positive relation-
ship between brand and generic approvals), suggesting that the presence of generic 
drugs might further innovation. ConClusions: It was shown that market size does 
affect the rates at which pharmaceuticals aim to bring their products to the market. 
While brand manufacturers react positively to increased market size, weak property 
rights do not appear to affect innovation output negatively.
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objeCtives: Oncology trials increasingly permit switching from standard care (SC) 
to the new treatment following disease progression. Methods to remove the effect 
of the active treatment in the SC arm are used by HTA agencies to estimate what 
the effect of the SC would’ve been had crossover not occurred. One method is using 
RPSFT models to derive counterfactual survival times without crossover. For CE 
modeling, these counterfactual survival times need to be parametrically extrapo-
lated to estimate life expectancy. It is known that the RPSFT approach introduces 
additional uncertainty and e.g. the standard error of a hazard ratio calculated from 
counterfactual survival times needs to be inflated. Traditional methods of para-
metric survival analysis don’t account for this increased uncertainty which could 
influence allocation decisions. Methods: A dataset of 400 patients was simulated 
assuming a Weibull distribution for PFS and OS with 70% of the patients in the SC 
arm switching after progression. Life expectancy was calculated in two scenarios. In 
scenario 1 the RPSFTM adjusted OS had Weibull parameter estimates and covariance 
calculated directly from the counterfactual survival times. In scenario 2 the data 
was bootstrapped 1000 times. For each iteration a new RPSFT model, associated 
counterfactual survival times and Weibull functions were fitted. The mean and 
covariance of these 1000 parameter estimates was taken. Results: Mean incre-
mental life expectancy after adjusting for cross-over was the same with and without 
bootstrapping. When PSA was run, larger confidence intervals in the scenario with 
bootstrapping indicated, the traditional approach failed to account for the increased 
uncertainty and underestimated the probability of the new treatment being less 
efficacious (0.4% without compared to 13.4% with bootstrapping). ConClusions: 
Failing to appropriately reflect the uncertainty underlying parameter estimates of 
crossover adjusted survival times could impact HTA decisions when appraisals are 
based on the likelihood of a treatment being cost effective.
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objeCtives: Reporting of survival outcomes from clinical trials is often limited to 
median survival times, hazard ratios, Kaplan-Meier curves and numbers at risk. 
The numerical results are not always sufficient for meta-analysis and cost-effec-
tiveness analysis. Further information can be obtained by digitizing and analysing 
the Kaplan-Meier curves. The most basic analysis approach is to fit a non-linear 
model to the Kaplan-Meier curve and use this to estimate parameters such as the 
mean survival time. Methods have recently been developed for estimating individual 
patient data (IPD) from Kaplan-Meier curves. Once individual patient data is esti-
mated, standard survival analysis approaches can be used to estimate parameters 
and also provide estimates of uncertainty in the curve fits. The objective of this 
study was to review the methods commonly used and assess the impact of the 
improved methods, where IPD is estimated, on the inferences drawn. Methods: 
We conducted a systematic review of the methods that have been used in NICE HTAs 
to obtain data from published Kaplan-Meier curves. We examined the frequency 
of each method, how results were used and any feedback from Evidence Review 
Groups. Improved methods, estimating IPD, were applied to a selection of studies 
where this was not conducted in the original analysis. The impact of the improved 
methods on the conclusions of the studies was assessed. Results: The review 
showed that most HTAs used non-linear models to approximate the Kaplan-Meier 
curves. It also showed that the improved methods, estimating IPD, can have a sig-
nificant impact on conclusions drawn from survival results. ConClusions: The 
estimation of IPD from Kaplan-Meier curves is a valuable method that is currently 
underutilised. It has the potential to provide better estimates of survival param-
eters and to improve the characterisation of uncertainty in such estimates. This is 
especially important when survival curves are extrapolated.
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objeCtives: Evolution of asthma disease severity over time can be highly depend-
ent on the prescription patterns and drug compliance of patients. The purpose of 
the modeling is to analyze longitudinal observational data of cohort of asthma 
patients to describe and quantify the dynamics of adherence, prescriptions, and 
outcomes and their interaction over time. Methods: We explored and analyzed 
5 different observational studies following asthma patients in France over up to 
2 years. Main patients’ demographics along with prescriptions, ACT and 3-level 
GINA control scores could be defined every quarter and exacerbations at a given 
quarter were adjucated based on hospital admissions. Medication possession 
ratios could be defined quarterly and used as a proxy for adherence. A patient-
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objeCtives: While the follow-up time on Ipilimumab trials is in excess of 4 years, 
HTA models often require survival to be extrapolated to 10 years and beyond. 
However, patient level data on prognostic factors are rarely available; hence 
extrapolation methods assume a homogeneous study population and are based 
on statistical considerations only. Such approaches are criticized for disregarding 
clinical reality and may be biased. In this study a survival extrapolation model 
that accounted for heterogeneity was developed based on both statistically and 
clinically relevant considerations. The method was applied on survival data in 
patients with Metastatic Melanoma. Methods: Survival data were taken from 
a randomized controlled clinical trial that compared dacarbazine plus placebo 
versus dacarbazine plus ipilimumab. Two parametric models were explored to 
extrapolate survival: a model assuming no heterogeneity in patients and another 
model that divided patients into three subgroups based on cancer stage observed 
at baseline and additionally included subpopulations of a priori unobserved long-
term survivors. Survival of the subpopulations was extrapolated and summed 
to obtain survival in the overall population. Subgroup formation was guided by 
expert opinion of oncologists. The statistical and clinical validity of the models 
were assessed. Results: Among commonly used distributions (exponential, 
Weibull, lognormal) the lognormal distribution fitted the survival data best in 
the no-heterogeneity model whereas Weibull distribution was used for the het-
erogeneity model. For statistical validity, both models fitted the data reasonably 
well. However, the no-heterogeneity model underestimated the long tail of the 
survival curves. The no-heterogeneity model implied decreasing mortality over 
time while the heterogeneity model implied increasing mortality, which is more 
clinically relevant. ConClusions: The no-heterogeneity model fitted the data 
reasonably well but was not relevant for extrapolation from a clinical perspective. 
The heterogeneity model captured the long tail of the survival curve best, and 
provided a statistically and clinically relevant model.
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objeCtives: A three-state Markov model for cost-effectiveness analysis of cancer 
treatments requires information on both progression-free survival (PFS) and over-
all survival (OS). However, data is not always available on both of these outcomes. 
The objective of this study is to perform a Bayesian bivariate indirect comparison 
meta-analysis (BICMA) to obtain estimates of both PFS and OS for use in a cost-
effectiveness analysis when data on these outcomes is incomplete. Methods: In 
a UK Health Technology Assessment report on cost-effectiveness assessment of 
docetaxel with prednisone/prednisolone for the treatment of hormone-refractory 
metastatic prostate cancer, a two-state Markov model was specified using OS data 
from a single randomised controlled trial that did not report PFS. We propose the 
use of a Bayesian BICMA model that jointly estimates OS and PFS, and which in turn 
allows for the specification of a three-state Markov model incorporating a post-pro-
gression phase. Survival data for the trials included in the BICMA were reconstructed 
from survival curves, presented in the articles reporting the trials, using the method 
proposed by Guyot et. al. (BMC Med Res Methodol 2012;12:9) using the DigitizeIt and 
R software. Results: The Bayesian BICMA model was designed to jointly model 
the correlated outcomes: OS and PFS using either non-informative or informative 
prior distribution on the correlation between the outcomes. An informative prior 
distribution on the correlation between PFS and OS was based on external evidence 
using prostate cancer trials presented in Halabi et. al. (Clin Oncol 2009;27(17):2766-
71). Modelling the correlated outcomes jointly using this bivariate model allows 
prediction of PFS for the comparison of interest. ConClusions: In the absence of 
evidence on PFS, required for the specification of a three-state Markov model, the 
proposed method allows PFS to be constructed thus eliminating the need to reduce 
the cost-effectiveness analysis to a two-state Markov model.
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objeCtives: To examine factors determining the level of innovation in an organisa-
tion, examining two factors – market size and the strength of intellectual property 
rights for a particular drug class Methods: The pharmaceutical industry is used 
as a case study as it not only relies heavily on R&D, but, with the division between 
brand name and generic drugs, can provide insight into how the removal of intel-
lectual property rights might affect innovation. The estimation models were based 
on an economic model for innovation and market size developed by Acemoglu and 
Linn (2004). Drug approval data obtained from the US FDA was used for the innova-
tion variable; a measure for market size was constructed using prescribed medi-
cines expenditure data from the US Medical Expenditure Panel Survey. The analysis 
focussed on examining the relationships between the variables using various statis-
tical estimation techniques, starting with a simple OLS log-log model, more general 
negative binomial and gamma models, as well as fully flexible non-linear smoothing 
regressions in the form of feed-forward neural networks. Results: Brand name 
approvals increased by 2.64% and generic approvals by 4.2% for a 1% increase in 
income-based market size. The presence of generic drugs and, thus, weak intel-
lectual property rights did not appear to have a negative effect on research and 
